<DOC>
	<DOCNO>NCT00418379</DOCNO>
	<brief_summary>A phase III study evaluate Long term efficacy , carry-over effect safety 300 IR sublingual Immunotherapy ( SLIT ) tablet adults patient suffer grass pollen rhinoconjunctivitis</brief_summary>
	<brief_title>Phase III Study Assess Long Term Efficacy , Carry-over Effect Safety 300 IR Sublingual Immunotherapy Tablets</brief_title>
	<detailed_description />
	<criteria>Male female outpatient age 18 50 year Grass pollenrelated allergic rhinoconjunctivitis least last two pollen season Positive SPT specific IgE value least Class 2 grass pollen allergens A score great equal 12 possible 18 Retrospective Rhinoconjunctivitis Total Symptom Score ( RRTSS ) Patients symptoms rhinoconjunctivitis grass pollen season due sensitisation allergen grass pollen must include . Patients must asymptomatic allergen grass pollen season . Patients allergic rhinitis due perennial allergen may include . Asthma require treatment beta2 inhaled agonist . Patients receive desensitisation treatment grass pollen allergen within previous 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Grass pollen tablet</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>